In Its Second Biotech Deal In Three Months, Ranbaxy Signs Pact With Pfenex For An Undisclosed Biosimilar
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Moving one step closer to realizing its ambitions in the fast-emerging biosimilars space, Daiichi Sankyo's Indian arm Ranbaxy signed a development deal with the San Diego-based Pfenex, a spin-off of the Dow Chemical Company